351 related articles for article (PubMed ID: 30764623)
21. The efficacy of human papillomavirus vaccination in the prevention of recurrence of severe cervical lesions.
Sehnal Borek; Pichlík Tomáš; Halaška Michael J; Větrovská Monika; Babková Anna; Drozenová Jana; Robová Helena; Rob Lukáš
Ceska Gynekol; 2023; 88(4):294-300. PubMed ID: 37643912
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
Haupt RM; Sings HL
J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
[TBL] [Abstract][Full Text] [Related]
23. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
[TBL] [Abstract][Full Text] [Related]
24. [Human papillomavirus nonavalent vaccine. Update 2017].
Bosch FX; Moreno D; Redondo E; Torné A
Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
McIntosh J; Sturpe DA; Khanna N
J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
[TBL] [Abstract][Full Text] [Related]
26. [Human papillomavirus vaccines].
Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
28. Decreasing risk: impact of HPV vaccination on outcomes.
Hymel PA
Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
[TBL] [Abstract][Full Text] [Related]
29. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus: current status and issues of vaccination.
Malik H; Khan FH; Ahsan H
Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
[TBL] [Abstract][Full Text] [Related]
31. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
33. Safety of HPV vaccines in the age of nonavalent vaccination.
Quattrone F; Canale A; Filippetti E; Tulipani A; Porretta A; Lopalco PL
Minerva Pediatr; 2018 Feb; 70(1):59-66. PubMed ID: 29363293
[TBL] [Abstract][Full Text] [Related]
34. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
[TBL] [Abstract][Full Text] [Related]
35. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
36. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
37. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
38. Human papillomavirus vaccines and vaccine implementation.
de Sanjosé S; Alemany L; Castellsagué X; Bosch FX
Womens Health (Lond); 2008 Nov; 4(6):595-604. PubMed ID: 19072462
[TBL] [Abstract][Full Text] [Related]
39. [Protection against uterine cervical cancer by HPV vaccines].
Inoue M
Uirusu; 2008 Dec; 58(2):155-63. PubMed ID: 19374193
[TBL] [Abstract][Full Text] [Related]
40. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
